acetohexamide

Trade name: dymelor

Small moleculeapproved

Approved

Dec 23, 1964

Acetohexamide (trade name Dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone. It lowers blood sugar by stimulating the pancreatic beta cells to secrete insulin and by helping the body use insulin efficiently. The pancreas must produce insulin for this medication to work. Acetohexamide binds to an ATP-dependent K+ channel on the cell membrane of pancreatic beta cells. This inhibits a tonic, hyperpolarizing out flux of potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granule with the cell membrane, and therefore increased secretion of (pro) insulin. Acetohexamide extensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide. Hydroxyhexamide is believed to be responsible for prolonged hypoglycemic effects. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma. Acetohexamide has been discontinued in the US market. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 4 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1960s

  1. Dec 23, 1964

    Eli Lilly — Earliest FDA Approval

  2. Dec 23, 1964

    Eli Lilly — NDA Organization

1980s

  1. Feb 9, 1987

    Ani Pharmaceuticals — Marketing Organization

  2. Nov 25, 1987

    Teva — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewDec 23, 1964

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2
Mol. weight
324.395 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-n-(cyclohexylcarbamoyl)benzenesulfonamide
  • 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-n-(cyclohexylcarbamoyl)benzenesulfonamide
  • 1-((p-acetylphenyl)sulfonyl)-3-cyclohexylurea
  • 1-((p-acetylphenyl)sulfonyl)-3-cyclohexylurea
  • 33006
  • 33006
  • acetohexamid
  • acetohexamid
  • acetohexamid
  • acetohexamida
  • acetohexamida
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acetohexamide
  • acétohexamide
  • acétohexamide
  • acetohexamidum
  • acetohexamidum
  • dimelor
  • dimelor
  • dymelor
  • dymelor
  • dymelor
  • dymelor
  • dymelor
  • dymelor
  • dymelor
  • n-(p-acetylphenylsulfonyl)-n'-cyclohexylurea
  • n-(p-acetylphenylsulfonyl)-n'-cyclohexylurea

Organizations

Marketing (6)

OrganizationOrg typeRelationshipDate
Ani PharmaceuticalsFor profitMKTGFeb 9, 1987
Ani PharmaceuticalsFor profitSYNFeb 9, 1987
Eli LillyFor profitSYNDec 23, 1964
Eli LillyFor profitNDADec 23, 1964
TevaFor profitMKTGNov 25, 1987
Upsher-Smith LaboratoriesFor profitMKTG